Leerink Initiates Coverage of Danaher With Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb) – Leerink today initiated coverage of Danaher with an Outperform rating and a $93 price target on the firm's shares. 

"We believe the forthcoming company separation allows for a sharpened focus and expanded capital deployment opportunities," analyst Dan Leonard said in a report, adding that he also sees a margin expansion opportunity. All of those factors combined should drive Danaher's stock to outperform the S&P, he said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.